ADARx Pharmaceuticals, Inc. (ADRX) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Recent news

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
ADRX

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
ADRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is focused on advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs.
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.0 | -9.5 |



